ScripAlmirall CEO Carlos Gallardo has added his voice to calls by leaders in the pharmaceutical industry for Europe to create a more innovation-friendly environment before it slips even further behind the
ScripThese are interesting times for Almirall and CEO Carlos Gallardo believes the Spanish firm holds “a unique position as the only company that focuses exclusively on medical dermatology and has capabili
ScripA decade ago, Almirall took the strategic decision to focus exclusively on medical dermatology, and after posting a strong set of financials for 2024, CEO Carlos Gallardo has told investors that “I’m
ScripAlmirall says that atopic dermatitis drug Ebglyss continues to make a promising start and is confident that its psoriasis drug Ilumetri will hit its €250m peak sales target for full-year 2024. Ebglyss